Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Innate immune recognition and suppression of tumors.

Hayakawa Y, Smyth MJ.

Adv Cancer Res. 2006;95:293-322. Review.

PMID:
16860661
2.

NKG2D and cytotoxic effector function in tumor immune surveillance.

Hayakawa Y, Smyth MJ.

Semin Immunol. 2006 Jun;18(3):176-85. Epub 2006 May 3. Review.

PMID:
16675266
3.

The innate immune response to tumors and its role in the induction of T-cell immunity.

Diefenbach A, Raulet DH.

Immunol Rev. 2002 Oct;188:9-21. Review.

PMID:
12445277
4.

T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.

Teng MW, Kershaw MH, Hayakawa Y, Cerutti L, Jane SM, Darcy PK, Smyth MJ.

J Biol Chem. 2005 Nov 18;280(46):38235-41. Epub 2005 Sep 16.

5.

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.

Cancer Res. 2005 Jul 15;65(14):6321-9.

6.

A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.

Diefenbach A, Hsia JK, Hsiung MY, Raulet DH.

Eur J Immunol. 2003 Feb;33(2):381-91.

7.

Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?

Zhang C, Zhang J, Wei H, Tian Z.

Int Immunopharmacol. 2005 Jul;5(7-8):1099-111. Epub 2005 Apr 1. Review.

PMID:
15914316
8.

NKG2D ligands: key targets of the immune response.

González S, López-Soto A, Suarez-Alvarez B, López-Vázquez A, López-Larrea C.

Trends Immunol. 2008 Aug;29(8):397-403. doi: 10.1016/j.it.2008.04.007. Epub 2008 Jul 3. Review.

PMID:
18602338
9.

ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D.

Blood. 2006 Aug 15;108(4):1313-9. Epub 2006 Apr 18.

10.

NKG2D and Related Immunoreceptors.

Strong RK, McFarland BJ.

Adv Protein Chem. 2004;68:281-312. Review.

PMID:
15500864
11.

NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.

Cerwenka A, Lanier LL.

Tissue Antigens. 2003 May;61(5):335-43. Review.

PMID:
12753652
12.

The role of the NKG2D receptor for tumor immunity.

Coudert JD, Held W.

Semin Cancer Biol. 2006 Oct;16(5):333-43. Epub 2006 Jul 8. Review.

PMID:
16914326
13.

Strategies for target cell recognition by natural killer cells.

Diefenbach A, Raulet DH.

Immunol Rev. 2001 Jun;181:170-84. Review.

PMID:
11513138
14.

MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M.

Cancer Res. 2003 Dec 15;63(24):8996-9006.

15.

NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.

Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, Kubin M, Soria JC, Chouaib S, Mami-Chouaib F.

J Immunol. 2005 Nov 1;175(9):5790-8.

16.
17.

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Jinushi M, Hodi FS, Dranoff G.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9190-5. Epub 2006 Jun 5.

18.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.

J Exp Med. 2005 Oct 17;202(8):1075-85.

19.

The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands.

Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeböller H, Brunner E, Zientkowska M, Herrmann T, Walter L, Alves F, Multhoff G, Dressel R.

J Immunol. 2007 Oct 15;179(8):5523-33.

20.

NKG2D ligands in tumor immunity.

Nausch N, Cerwenka A.

Oncogene. 2008 Oct 6;27(45):5944-58. doi: 10.1038/onc.2008.272. Review.

PMID:
18836475

Supplemental Content

Support Center